Format

Send to

Choose Destination
Clin Transl Oncol. 2017 Jul;19(7):785-792. doi: 10.1007/s12094-017-1613-6. Epub 2017 Jan 16.

Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential.

Author information

1
Neuro-Academy Research Group, Sisli, Istanbul, Turkey. maltinoz@gmail.com.
2
Department of Psychiatry and Psychology, Maastricht University Medical Centre, Maastricht, The Netherlands.
3
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
4
Department of Neurosurgery, Memorial Hospital, Sisli, Istanbul, Turkey.

Abstract

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

KEYWORDS:

Cancer; Immunotherapy; Rabies virus; Spontaneous remission

PMID:
28093702
DOI:
10.1007/s12094-017-1613-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center